Pharma Likelihood Of Approval
We are the trusted, gold standard intelligence provider to the world’s largest industries
GlobalData powers faster, more informed decisions with:
- Granular industry intelligence: We develop deep, vertical-specific intelligence tailored to your industry, providing 360° insight.​
- Exhaustive coverage: We synthesize our vast data universe into formats that support your decision-making needs, covering the sectors, themes, companies and geographies that matter to you. ​
- Proprietary datasets: We provide you with access to untapped pools of intelligence generated from our proprietary datasets and primary research capabilities. ​
- Robust methodologies: The quality and timeliness of our data is a key differentiator. We leverage robust research methodologies to turn millions of data points into trusted intelligence.
Thousands of companies, government organizations, and decision makers rely on GlobalData
We have a track record of serving truly diverse clients, including:
- Corporates: From helping the C-suite refine strategy to powering innovation in marketing and R&D, our corporate use cases are endless. ​
- Investment firms: We help financial analysts develop robust long-term strategies and get alpha signals before the rest. ​
- Professional services: We give consultants, legal, and accounting firms the critical insights to make faster, more informed decisions. ​
- Other sectors: From media to academia, we work with sectors as diverse as our data. ​
The trusted, actionable and future-proof insight you need to stay ahead
We have decades of experience in being the gold standard intelligence provider based on: ​
- Unique data: Proprietary datasets built from terabytes of data. Our unmatched intelligence gives you true strategic advantage.
- Expert analysis: Leverage collective expertise. Count on our extensive team of researchers, analysts, subject matter experts, and journalists, plus thousands of external thought-leaders.​
- Real intelligence over AI: Experience a level of analysis that leaves AI in the dust. Unlock the proprietary datasets unseen by AI and gain a decisive edge. ​
- Time-saving research solutions: Save hundreds of hours on research. Our comprehensive reports let you focus on delivering actionable insights - not searching for them. ​
- Unparalleled global coverage: Tap into insights from anywhere. Our extensive global coverage offers an unrivalled view of the market landscape.​
- One platform: Access all our unique data, expert analysis, and innovative solutions on one platform. ​
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Cebsulfase alfa in Metachromatic Leukodystrophy (MLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cebsulfase alfa in Metachromatic Leukodystrophy (MLD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cebsulfase alfa in Metachromatic Leukodystrophy (MLD)Drug Details:Cebsulfase alfa (TAK-611,SHP-611, HGT-1110, recombinant...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Icosabutate in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Icosabutate in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Icosabutate in Non-Alcoholic Steatohepatitis (NASH)Drug Details:Icosabutate (PRC-4016; PRB-01022) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Licogliflozin in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Licogliflozin in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Licogliflozin in Non-Alcoholic Steatohepatitis (NASH)Drug Details:licogliflozin was under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - OPK-88005 in Hemophilia A (Factor VIII Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPK-88005 in Hemophilia A (Factor VIII Deficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPK-88005 in Hemophilia A (Factor VIII Deficiency) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - OPK-88005 in Hemophilia B (Factor IX Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPK-88005 in Hemophilia B (Factor IX Deficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPK-88005 in Hemophilia B (Factor IX Deficiency) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - GI-6301 in Chordoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GI-6301 in Chordoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GI-6301 in Chordoma Drug Details: GI-6301 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Follitropin Delta in Male Infertility
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Follitropin Delta in Male Infertility report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Follitropin Delta in Male Infertility Drug Details: Follitropin delta (Rekovelle) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Peltopepimut-s in Penile Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Peltopepimut-s in Penile Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Peltopepimut-s in Penile CancerDrug Details:Peltopepimut-s (ISA-101) is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Dostarlimab in Neuroendocrine Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dostarlimab in Neuroendocrine Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dostarlimab in Neuroendocrine Carcinoma Drug Details: Dostarlimab (Jemperli) is a immunoglobulin G4...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - SUVND-4010 in Cognitive Impairment Associated With Schizophrenia (CIAS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SUVND-4010 in Cognitive Impairment Associated With Schizophrenia (CIAS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SUVND-4010 in Cognitive Impairment Associated With Schizophrenia (CIAS)Drug Details:SUVND-4010...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.